* eFFECTOR Therapeutics Inc EFTR.OQ reported a quarterly
adjusted loss of $3.42 per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-5.50. The mean expectation of
two analysts for the quarter was for a loss of $1.65 per share.
Wall Street expected results to range from $-3.21 to -9 cents
per share.
* Reported revenue was zero; analysts expected zero.
* eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of $3.42.
* The company reported a quarterly loss of $9.13 million.
* eFFECTOR Therapeutics Inc shares had risen by 5.5% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 45% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "buy."
Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $22.50
This summary was machine generated from LSEG data March 25 at
09:15 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -1.65 -3.42 Missed
Sep. 30 2023 -3.08 -3.25 Missed
Jun. 30 2023 -4.94 -4.25 Beat
Mar. 31 2023 -3.40 -6.00 Missed